NEFL and breast cancer: Huehnchen et al. [172] monitored NfL levels in a cohort of 31 patients treated with paclitaxel and compared NfL levels with healthy control (n = 6) and breast cancer patients not treated with chemotherapy (n = 25); they observed a specificity and sensibility higher than 80%, giving promising results even if the low number of subjects included in the analysis make a validation necessary in larger cohorts.